Arbutus Biopharma (ABUS) Enterprise Value (2016 - 2025)
Arbutus Biopharma (ABUS) has disclosed Enterprise Value for 16 consecutive years, with -$91.5 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 25.4% to -$91.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$91.5 million through Dec 2025, up 25.4% year-over-year, with the annual reading at -$91.5 million for FY2025, 25.4% up from the prior year.
- Enterprise Value hit -$91.5 million in Q4 2025 for Arbutus Biopharma, up from -$93.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$78.4 million in Q2 2021 to a low of -$165.5 million in Q1 2022.
- Historically, Enterprise Value has averaged -$127.7 million across 5 years, with a median of -$130.6 million in 2021.
- Biggest five-year swings in Enterprise Value: crashed 399.55% in 2021 and later surged 30.92% in 2025.
- Year by year, Enterprise Value stood at -$155.3 million in 2021, then grew by 5.41% to -$146.9 million in 2022, then rose by 14.23% to -$126.0 million in 2023, then increased by 2.68% to -$122.6 million in 2024, then increased by 25.4% to -$91.5 million in 2025.
- Business Quant data shows Enterprise Value for ABUS at -$91.5 million in Q4 2025, -$93.7 million in Q3 2025, and -$98.1 million in Q2 2025.